Delivery Order SPE2DB22D2206-SPE2DB26FDV19
Award Date 10/29/25
Potential Completion Date 11/20/25
Potential Value $8.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $6,934.96 for HYPERRAB 300 Unit/ML Vial 5ML on October 30, 2025, with completion expected by November 21, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for post-exposure prophylaxis in rabies prevention, supporting the federal...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $18,711.54 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HYPERRAB 300 Unit/ML (1 unit). This firm fixed-price delivery order, with completion scheduled for August 28, 2025, represents a competitive award with no set-aside designation. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion...
- The Defense Logistics Agency awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of September 4, 2025. This non-set-aside, competitively awarded contract operates under a firm fixed-price structure and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with a completion date of September 2, 2025. This is a firm fixed price contract with no set-aside designation, and the pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin used for post-exposure prophylaxis in rabies prevention, representing a critical...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by October 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $13,860.40 by the Defense Logistics Agency (DLA) for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed-price, non-set-aside contract was executed on October 17, 2025, with an ultimate completion date of November 7, 2025. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $21,489.60 and is scheduled for completion by September 29, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $1,732.55 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with an ultimate completion date of August 11, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken,...
- On September 3, 2025, the Defense Logistics Agency awarded a delivery order valued at $4,851.14 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for...